Purple AI, a company specializing in brain disease AI, announced that it has appointed Dr. Joshua N. Goldstein as a Scientific Advisory Board Member. Dr. Goldstein will provide scientific and clinical advice on Purple AI's overall AI research in stroke and neurocritical care.
Dr. Joshua N. Goldstein is a Professor of Emergency Medicine at Harvard Medical School, Vice Chair of Emergency Medicine at Mass General Brigham and Director of the Neuroemergency Center at Massachusetts General Hospital. He is recognized as a neuroemergency medicine expert who has pioneered research in early risk and prognosis assessment in the field of acute stroke and intracerebral hemorrhage.
Through this consulting agreement, Purple AI plans to secure clinical credibility for entry into the US market and strengthen the foundation for global business expansion. The company plans to gradually advance its research design to reflect the US clinical environment, establish a data verification system that complies with international regulatory standards, and expand collaboration with major North American medical institutions.
Based on its selection as a Deep Tech Tips company by the Ministry of SMEs and Startups in 2025, the company is expanding the development of an end-to-end AI platform that includes stroke (cerebral hemorrhage and cerebral infarction) diagnosis and prognosis prediction. Furthermore, its cerebral hemorrhage diagnosis AI solution, approved by the US Food and Drug Administration, is undergoing clinical trials at major North American hospitals, including UMass Memorial Health and White Rock Medical Center.
Dr. Goldstein stated that his collaboration with Purple AI will strengthen the scientific foundation for improving early diagnosis and treatment management of patients with stroke and cerebral hemorrhage.
- See more related articles
You must be logged in to post a comment.